Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer

J. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea)

Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism
Session: Diagnosis, prognostication and treatment of pulmonary embolism
Session type: Thematic Poster
Number: 3122
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea). Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer. 3122

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Direct oral anticoagulants and venous thromboembolism
Source: Eur Respir Rev 2016; 25: 295-302
Year: 2016



Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis
Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism
Year: 2020




Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism
Source: Eur Respir J 2002; 20: Suppl. 38, 237s
Year: 2002

Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin.
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019

Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism
Source: Eur Respir J 2001; 18: Suppl. 33, 381s
Year: 2001

Efficiency of r-TPA therapy in major venous thromboembolism
Source: Eur Respir J 2007; 30: Suppl. 51, 83s
Year: 2007

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment
Source: Eur Respir J 2016; 48: 1369-1376
Year: 2016



Treatment and prevention of cancer-associated venous thromboembolism
Source: Virtual Congress 2021 – Pulmonary embolism: controversies in management
Year: 2021


Risk of venous thromboembolism in lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 73s
Year: 2004

Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism
Source: Eur Respir J, 51 (4) 1800077; 10.1183/13993003.00077-2018
Year: 2018



Complications of anticoagulant therapy in patients with pulmonary thromboembolism
Source: Eur Respir J 2007; 30: Suppl. 51, 604s
Year: 2007

Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Year: 2021



Incidental venous thromboembolism, detected by chance, but still venous thromboembolism
Source: Eur Respir J, 55 (2) 2000028; 10.1183/13993003.00028-2020
Year: 2020



Venous thrombo-embolism prophylaxis
Source: Annual Congress 2009 - PG18 Practical clinical lessons in pulmonary vascular medicine: a case-based approach
Year: 2009


Efficacy and safety of treatment with anticoagulants in patients with unprovoked venous thromboembolism in Korea
Source: International Congress 2016 – Acute pulmonary embolism
Year: 2016


Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review
Source: Eur Respir J 2015; 45: 201-210
Year: 2015



Fixed or weight-adjusted dosis of enoxaparin as prophylaxis for venous thromboembolism in acutelly ill medical patients
Source: Eur Respir J 2004; 24: Suppl. 48, 273s
Year: 2004

Genetic and acquired risk factors of venous thromboembolism
Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=1
Year: 2004

Venous thromboembolic disease and bronchial cancer
Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach
Year: 2012

A single centre experience of low dose direct oral anticoagulants (DOAC) after unprovoked venous thromboembolism (VTE)
Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism
Year: 2019